An Open-Label, Multi-Center Phase I/II Study of the Safety and Tolerability of the Combination of Trastuzumab-MCC-DM1 (T-DM1) With Docetaxel, and Potentially Pertuzumab, for Treatment for Patients With Advanced Breast Cancer

Trial Profile

An Open-Label, Multi-Center Phase I/II Study of the Safety and Tolerability of the Combination of Trastuzumab-MCC-DM1 (T-DM1) With Docetaxel, and Potentially Pertuzumab, for Treatment for Patients With Advanced Breast Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Docetaxel (Primary) ; Trastuzumab emtansine (Primary) ; Pertuzumab
  • Indications Advanced breast cancer; Early breast cancer; Male breast cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 06 Apr 2016 Results (n = 98) published in the Annals of Oncology.
    • 14 Dec 2013 Results for the cohort of patients with early-stage breast cancer presented at the 36th Annual San Antonio Breast Cancer Symposium.
    • 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top